INS and metabolic disease: In humans, clinical trials aiming to boost endogenous NAD+ for treatment of metabolic diseases are increasing, showing promising results; for example, in postmenopausal women with prediabetes, a daily dose of NMN increases muscle insulin sensitivity45,134,149.